Singulair Switch Among Merck's OTC Possibilities
This article was originally published in The Tan Sheet
Executive Summary
Merck may seek an OTC switch of its best-selling Singulair prescription medication, most likely asking for a nonprescription indication for allergic rhinitis
You may also be interested in...
Merck's Frazier Promoted To CEO To Drive Post-Schering Success
Merck & Co. announced Nov. 30 it promoted current president Kenneth Frazier to CEO effective Jan. 1.
Merck Gives Consumer Health Care Division Direct Line To CEO
Merck is searching for an executive to lead its new consumer health care division to international growth once its $41.1 billion merger with Schering-Plough closes
Litigation In Brief
Antioxidant claims basis for FDA suit: In his third lawsuit filed against FDA in less than a month, attorney Jonathan Emord alleges FDA "created a rigid construct that categorically rejects a large quantum of peer-reviewed science," namely qualified health claims linking antioxidant vitamins C and E with reduced risk of site-specific cancers. Emord's 1complaint, filed Aug. 14 in the U.S. District Court for the District of Columbia, says FDA violated First Amendment-based precedent in denying the claims for which he petitioned in 2008. As with the similar recent suit Emord filed against FDA for rejecting selenium QHCs, the Clifton, Va.-based attorney represents the Alliance for Natural Health U.S., the Coalition to End FDA and FTC Censorship, and businesspeople Durk Pearson and Sandy Shaw (2"The Tan Sheet" Aug. 3, 2009, In Brief)